Durvalumab and Tremelimumab for Pediatric Malignancies



Status:Recruiting
Conditions:Cancer, Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 17
Updated:3/23/2019
Start Date:March 7, 2019
End Date:March 20, 2023
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab
(immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and
expand in a second phase to test the efficacy of these drugs once this dose is determined.

This is a first time in pediatrics study primarily designed to evaluate the safety and
tolerability of durvalumab and durvalumab in combination with tremelimumab at increasing
doses in pediatric patients with advanced solid malignancies and hematological malignancies
(including lymphomas) and for whom no standard of care treatments exist. Although treatment
efficacy is not a primary objective of this study given its early phase nature, the patients
screened for this study have no curative options and this study offers the potential of some
benefit.

The study will also characterize the PK of durvalumab and durvalumab in combination with
tremelimumab in children and adolescents and explore potential biological activity and
immunogenicity by assessing pharmacodynamics, anti drug antibody (ADA) levels, and anti-tumor
activity. The results from this trial will form the basis for decisions for potential future
pediatric studies.

Inclusion Criteria:

- Max Age =17 years

- Solid Tumors (except primary central nervous system malignant tumors): Patients must
have a histopathologic confirmation of malignancy. Patients must have progressed or
are refractory to standard therapies, and for whom no standard of care treatments
exist

- Malignant neoplasms of hematopoietic and lymphoid tissue and myelodysplastic syndrome:
pathologically confirmed relapsed or refractory advanced hematological malignancies
including lymphoma and acute leukemia

- Provision of diagnostic tumor sample mandated if available

- Evaluable disease

- No prior exposure to immune-mediated therapy

- Adequate organ and marrow function

- Life expectancy of at least 3 months

Exclusion Criteria:

- History of allogeneic organ transplantation (exceptions may be allowed for HL, NHL,
ALL and AML, after discussion with Sponsor). History of autologous bone marrow
transplant may be allowed (after discussion with Sponsor).

- Active or prior documented autoimmune or inflammatory disorders (exceptions)

- Uncontrolled intercurrent illness

- History of primary immunodeficiency

- Active infection including tuberculosis, hepatitis B, C or HIV

- Any unresolved toxicity NCI CTCAE version 5.0 Grade ≥2 from previous anticancer
therapy (exceptions)
We found this trial at
7
sites
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Lille Cedex,
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials